Inovio Pharmaceuticals 주식 (NASDAQ: INO)

에 대한 최신 뉴스 Inovio Pharmaceuticals (NASDAQ:INO) 주식

Inovio Pharmaceuticals

Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

AVGO

COST

금요일(13일) 아침 미국 주식 선물이 혼조세를 보이는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식은 다음과 같다. RH, 브로드컴, 51토크 온라인, 이노비오 및 코스트코

금요일 주목해야 할 주식: RH, 브로드컴, 51토크 온라인, 이노비오 및 코스트코

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals Inc

Innodata Inc

IN OVATIONS HOLDINGS INC by In Ovations Holdings, Inc.

In Ovations Holdings Inc

TPT Strategic Inc

Predictiv AI Inc

Innovator ETFs Trust Innovator International Developed Power Buffer ETF November

InfoNow Corp

<h3>Gainers</h3>
<ul>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock moved upwards by 18.7% to $4.31 during Friday's pre-market session. The market value of their outstanding shares is at $46.4 million. </li>
<li>Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) shares rose 16.0% to $0.5. The market value of their outstanding shares is at $297.7 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock rose 15.81% to $2.49. The market value of their outstanding shares is at $28.6 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) stock rose 13.62% to $13.18. The company's market cap stands at $21.8 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares rose 13.33% to $3.91. The company's market cap stands at $3.7 million. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) stock moved upwards by 12.82% to $0.93. The market value of their outstanding shares is at $36.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) stock decreased by 41.0% to $2.34 during Friday's pre-market session. The market value of their outstanding shares is at $99.5 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares declined by 32.48% to $2.54. The company's market cap stands at $66.2 million. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) stock fell 30.62% to $6.8. The market value of their outstanding shares is at $220.8 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares fell 20.84% to $0.19. The company's market cap stands at $20.5 million. </li>
<li>Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) stock declined by 15.77% to $16.94. The company's market cap stands at $1.1 billion. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) shares decreased by 14.15% to $2.19. The market value of their outstanding shares is at $431.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BCYC

BRNS

CADL

CVKD

ESPR

ISPC

LTRN

RPTX

SENS

12 Health Care Stocks Moving In Friday's Pre-Market Session

U.S. stocks traded mixed toward the end of trading, with the S&amp;P 500 edging lower on Friday.
The Dow traded down 0.14% to 43,851.19 while the NASDAQ rose 0.04% to 19,911.75. The S&amp;P 500 also fell, dropping, 0.04% to 6,048.90.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a>
Leading and Lagging Sectors Information technology shares jumped by 0.3% on Friday.
In trading on Friday, materials shares fell by 1.1%.
Top Headline
U.S. import prices increased by 0.1% from the previous month in November. Export prices came in unchanged for November compared to a 1% gain in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>WISeKey International Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) shares shot up 86% to $6.09 following the company's confirmation of its subsidiary WISeSat.Space's satellite launch with SpaceX. The goal of the launch is to deploy post-quantum-ready next-generation WISeSat satellites. This will showcase the combination of WISeKey's Root of Trust and SEALSQ's Post-Quantum Chips, providing security against emerging quantum threats.</li>
<li>Shares of Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) got a boost, surging 22% to $220.24 after the company posted better-than-expected earnings for its fourth quarter.</li>
<li>RH &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) shares were also up, gaining 13% to $430.78 after the company raised its guidance. Also, Baird maintained a Neutral rating on the stock and raised its price target from $300 to $400.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) shares dropped 57% to $1.6895 after the company reported results of Lunresertib and Camonsertib combination from MYTHIC Phase 1 gynecologic expansion clinical trial.</li>
<li>Shares of 22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) were down 35% to $0.0480 after the company announced a 1-for-135 reverse stock split.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) was down, falling 38% to $2.34 after the company announced a public offering of 10 million shares for gross proceeds of $30 million.</li>
</ul>
Commodities In commodity news, oil traded up 1.8% to $71.25 while gold traded down 1.3% at $2,675.00.
Silver traded down 1.8% to $31.050 on Friday, while copper fell 1.1% to $4.1985.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.53%, Germany's DAX fell 0.10% and France's CAC 40 fell 0.15%. Spain's IBEX 35 Index slipped 0.11%, while London's FTSE 100 fell 0.14%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 0.95%, Hong Kong's Hang Seng Index dipping 2.09%, China's Shanghai Composite Index tumbling 2.01% and India's BSE Sensex gaining 1.04%.
Economics
<ul>
<li>U.S. import prices increased by 0.1% from the previous month in November.</li>
<li>U.S. export prices came in unchanged for November compared to a 1% gain in the previous month.</li>
<li>The total number of active U.S. oil rigs came in unchanged at 482 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42483544/how-to-earn-500-a-month-from-meta-stock">How To Earn $500 A Month From Meta Stock</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

WKEY

XXII

Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet

U.S. stocks traded lower midway through trading, with the Nasdaq Composite down around 0.2% on Friday.
The Dow traded down 0.20% to 43,824.10 while the NASDAQ fell 0.17% to 19,869.43. The S&amp;P 500 also fell, dropping, 0.14% to 6,042.84.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a>
Leading and Lagging Sectors Utilities shares jumped by 0.3% on Friday.
In trading on Friday, communication services shares fell by 0.8%.
Top Headline
Shares of RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) rose around 15% on Friday after the company released quarterly results.
RH posted downbeat earnings and sales results for its third quarter. However, the company raised revenue guidance across the board based on current trends. The company expects fourth-quarter demand growth of 20% to 22%, and fourth-quarter revenue growth of 18% to 20%, according to data from Benzinga Pro.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>WISeKey International Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) shares shot up 97% to $6.46. WISeKey announced WISeSat satellite launch with SpaceX on Jan. 14, 2025.</li>
<li>Shares of Loop Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOOP#NASDAQ">LOOP</a>) got a boost, surging 38% to $1.7020. Loop Industries completed convertible preferred financing with Reed Societe Generale Group.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares were also up, gaining 20% to $16.38.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) shares dropped 50% to $1.9987 after the company reported results of Lunresertib and Camonsertib combination from MYTHIC Phase 1 gynecologic expansion clinical trial.</li>
<li>Shares of 22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) were down 37% to $0.0461 after the company announced a 1-for-135 reverse stock split.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) was down, falling 41% to $2.2350 after the company announced a public offering of 10 million shares for gross proceeds of $30 million.</li>
</ul>
Commodities In commodity news, oil traded up 1.4% to $70.97 while gold traded down 1% at $2,682.30.
Silver traded down 2% to $30.985 on Friday, while copper fell 1.2% to $4.1940.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.53%, Germany's DAX fell 0.10% and France's CAC 40 fell 0.15%. Spain's IBEX 35 Index slipped 0.11%, while London's FTSE 100 fell 0.14%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 0.95%, Hong Kong's Hang Seng Index dipping 2.09%, China's Shanghai Composite Index tumbling 2.01% and India's BSE Sensex gaining 1.04%.
Economics
<ul>
<li>U.S. import prices increased by 0.1% from the previous month in November.</li>
<li>U.S. export prices came in unchanged for November compared to a 1% gain in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42483544/how-to-earn-500-a-month-from-meta-stock">How To Earn $500 A Month From Meta Stock</a></li>
</ul>

LOOP

SOUN

Crude Oil Gains Over 1%; RH Shares Jump On Strong Forecast

U.S. stocks traded mixed this morning, with the Dow Jones index down around 0.1% on Friday.
Following the market opening Friday, the Dow traded down 0.09% to 43,874.75 while the NASDAQ rose 0.42% to 19,987.05. The S&amp;P 500 also rose, gaining, 0.14% to 6,059.64.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a>
Leading and Lagging Sectors Information technology shares jumped by 1% on Friday.
In trading on Friday, materials shares fell by 1.1%.
Top Headline
Shares of Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) jumped around 22% on Friday after the company posted better-than-expected earnings for its fourth quarter.
The company said it sees first-quarter revenue of approximately $14.6 billion, versus the $14.612 billion estimate. The company also issued adjusted EBITDA guidance of approximately 66 percent of projected revenue for the first quarter.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>WISeKey International Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) shares shot up 75% to $5.74. WISeKey announced WISeSat satellite launch with SpaceX on Jan. 14, 2025.</li>
<li>Shares of Loop Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOOP#NASDAQ">LOOP</a>) got a boost, surging 35% to $1.6693. Loop Industries completed convertible preferred financing with Reed Societe Generale Group.</li>
<li>TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) shares were also up, gaining 35% to $0.7034 after jumping around 18% on Thursday.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) shares dropped 48% to $2.08 after the company reported results of Lunresertib and Camonsertib combination from MYTHIC Phase 1 gynecologic expansion clinical trial.</li>
<li>Shares of 22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) were down 42% to $0.0425 after the company announced a 1-for-135 reverse stock split.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) was down, falling 40% to $2.2701 after the company announced a public offering of 10 million shares for gross proceeds of $30 million.</li>
</ul>
Commodities In commodity news, oil traded up 0.9% to $70.65 while gold traded down 1.2% at $2,676.40.
Silver traded down 2.5% to $30.830 on Friday, while copper fell 1.2% to $4.1950.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.55%, Germany's DAX fell 0.15% and France's CAC 40 fell 0.18%. Spain's IBEX 35 Index slipped 0.14%, while London's FTSE 100 fell 0.33%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 0.95%, Hong Kong's Hang Seng Index dipping 2.09%, China's Shanghai Composite Index tumbling 2.01% and India's BSE Sensex gaining 1.04%.
Economics
<ul>
<li>U.S. import prices increased by 0.1% from the previous month in November.</li>
<li>U.S. export prices came in unchanged for November compared to a 1% gain in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42483544/how-to-earn-500-a-month-from-meta-stock">How To Earn $500 A Month From Meta Stock</a></li>
</ul>

TRUG

US Stocks Mixed; Broadcom Shares Surge On Upbeat Earnings

Inovio Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares are trading lower by 40% to $2.23 during Friday&#8217;s session after the company <a href="https://www.benzinga.com/pressreleases/24/12/n42481116/inovio-announces-pricing-of-30-million-public-offering">priced a public offering</a> of 10 million shares of common stock and accompanying warrants.
The shares are priced at $3.00 each, with warrants exercisable at $3.76 per share, potentially raising $30 million in gross proceeds before expenses and commissions.
The offering, managed by Oppenheimer &amp; Co., Citizens JMP and Stephens Inc., is set to close on December 16, pending customary conditions.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42483141/hershey-merger-talks-fail">Hershey Merger Talks Melt: Did High Cocoa Prices, Mondelez Buyback Program Hurt Deal?</a>
<h2 class="wp-block-heading">Should I Sell My INO Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Inovio Pharmaceuticals have decreased by 51.14% in the past year. An investor who bought shares of Inovio Pharmaceuticals at the beginning of the year would take a loss of $4.49 per share if they sold it today. The stock has fallen 52.2% over the past month, meaning an investor who bought shares on Nov. 1 would see a capital loss of $3.24.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
INO has a 52-week high of $14.75 and a 52-week low of $2.20.

Why Inovio Pharmaceuticals (INO) Stock Is Down 40%

WIIM

Inovio Pharmaceuticals shares are trading lower after the company announced a public offering of 10 million shares for gross proceeds of $30 million.

Biotech

Health Care

Financing

Offerings

General

Inovio Pharmaceuticals Priced An Underwritten Public Offering Of 10M Shares And Accompanying Warrants To Purchase 10M Shares At An Exercise Price Of $3.76/Share, At A Combined Public Offering Price Of $3/Share And Accompanying Warrant, With Gross Proceeds Of $30M

U.S. stock futures advanced on Friday in premarket hours after declining in trade on Thursday. The futures of all four major indices were trading higher.
The 10-year and two-year Treasury notes yielded 4.33% and 4.19%, respectively. Traders await the import price index data, which will be released later today.
Wall Street is waiting for the Federal Reserve&#8217;s policy meeting next week. Federal Reserve officials are currently in a quiet period ahead of their December meeting.
November inflation data was in line with analyst expectations, shooting up the probability of a further 25 basis point rate cut in December rose to 96.7% versus 86% probability a week ago, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group&#8217;s FedWatch tool.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.65%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.33%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.23%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.29%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.41% to $606.79&nbsp;and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) jumped 0.76% to $530.49, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
<a href="https://www.benzinga.com/news/earnings/24/12/42478606/dow-dips-more-than-200-points-following-inflation-data-nvidia-and-amd-decline-fear-greed-index-remains-in-neutral-zone">U.S. stocks closed lower</a> on Thursday, with the Dow Jones shedding over 200 points. The market reacted to fresh inflation data and weaker-than-expected guidance from tech giants.
Technology stocks were among the day&#8217;s biggest losers. Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares dipped over 1%, while Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) plummeted more than 13% after issuing a disappointing 2025 outlook.
On the economic front, initial jobless claims rose to 242,000, higher than the estimated 220,000. Core producer prices increased by 0.2% month-over-month, aligning with market expectations.
Most S&amp;P 500 sectors ended the day in the red, with healthcare, consumer discretionary, and communication services bearing the brunt of the decline.
However, consumer staples bucked the trend and closed higher.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.66%</td>
<td>19.902.84</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.54%</td>
<td>6,051.25</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.53%</td>
<td>43,914.12</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.38%</td>
<td>2,361.08</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Picking up from Thursday&#8217;s session, Jason Goepfert, the founder of SentimenTrader, said, &#8220;This will be the S&amp;P 500&#8217;s 9th consecutive session with negative breadth. That&#8217;s happened fewer than 20 times in ~70 years. On average, the S&amp;P has been -12% from its high during these streaks.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This will be the S&amp;P 500&#39;s 9th consecutive session with negative breadth. That&#39;s happened fewer than 20 times in ~70 years. On average, the S&amp;P has been -12% from its high during these streaks. Today marks the closest the S&amp;P has been to its high. The 2 most similar were Dec… <a href="https://t.co/rxHkoG1AzD">pic.twitter.com/rxHkoG1AzD</a>
&mdash; Jason Goepfert (@jasongoepfert) <a href="https://twitter.com/jasongoepfert/status/1867309528573956329?ref_src=twsrc%5Etfw">December 12, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Talking about the future of AI, BlackRock in their 2025 outlook said, &#8220;We think the AI mega force will benefit U.S. stocks more and that's why we stay overweight, particularly relative to international peers such as European stocks.&#8221;
The note added that the &#8220;key signposts&#8221; for them to change their views will include any &#8220;surge in long-term bond yields or an escalation in trade protectionism.&#8221;
The note also added that BlackRock has conviction in U.S. equities outperforming their international peers. &#8220;We recognize valuations are rich in U.S. equities but don't see them as a near-term market driver,&#8221; it added.
According to Charles Schwab&#8217;s 2025 outlook, the volatility backdrop is likely to be different from what investors got used to in 2024. &#8220;The likelihood of a similar dynamic in 2025 is low, in our opinion,&#8221; the note said.
&#8220;Starting with where we are now, though, the market is in a relatively healthy position. As shown in the chart below, the S&amp;P 500 is comfortably above its 50 and 200-day moving averages; and when its 50 DMA was above its 200 DMA historically, the average annualized gain for the index (going back to the late 1920s) was 9.2%. There is strong momentum heading into the new year.&#8221;
However, &#8220;If inflation volatility picks back up, which will become clearer after tariff and labor policy implementations, there could be more risks to stocks via bonds,&#8221; Schwab note adds.
See Also:&nbsp;<a href="https://www.benzinga.com/money/how-to-trade-futures" target="_blank" rel="noreferrer noopener">How To Trade Futures</a>
Upcoming Economic Data
<ul>
<li>On Friday, the import price index data will be released at 8:30 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) was 14.38% up in premarket after it saw a four-fold increase in AI connectivity revenue driven by Tomahawk and Jericho shipments. The management also highlighted a significant reduction in VMware spending in the fourth quarter.</li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) was up 17.23% after it raised revenue guidance across the board based on current trends.</li>
<li>Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) was up 0.3% in premarket after it reported its first-quarter revenue and earnings per share, which beat analyst estimates.</li>
<li>Inovio Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) was down 22.61% after it announced a proposed public offering.</li>
<li>Loop Industries Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOOP#NASDAQ">LOOP</a>) gained 51.22% as completed convertible preferred financing with Reed Societe Generale Group.</li>
<li>Repare Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) tumbled 38.29% after it reported results of the Lunresertib and Camonsertib combination from MYTHIC Phase 1 gynecologic expansion clinical trial.</li>
<li>Candel Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAD#NASDAQ">CAD</a>) fell 31.12% after the company announced the pricing of its public offering.</li>
<li>Amentum Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTM#NYSE">AMTM</a>) was up 0.6% ahead of its earnings which are slated to be released before the opening bell. Analysts expect the company to report quarterly earnings at 25 cents per share.</li>
<li>Investors are awaiting earnings results from 51Talk Online Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COE#NYSE">COE</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures rose in the early New York session by 1.19% to hover around $70.86 per barrel.
The gold spot index fell by 0.88% to $2,685.59 per ounce. The Dollar Index was up 0.01% to 106.964 level.
Most Asian markets declined on Friday including Australia&#8217;s ASX 200, Hong Kong&#8217;s Hang Seng, China&#8217;s CSI 300, and Japan&#8217;s Nikkei 225. India&#8217;s S&amp;P BSE Sensex and South Korea&#8217;s Kospi Index, bucked the trend as they advanced. Most European markets advanced.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42460199/jpmorgan-reiterates-underweight-rating-on-supermicro-maintains-the-lowest-target-price-among-the-17-tracked-analysts">SMCI Stock Receives Harshest Price Target Among 17 Tracked Analysts As JPMorgan Maintains Underweight Rating On Super Micro</a></li>
</ul>
Photo courtesy: Wikimedia

Market Summary

Futures

Economics

Federal Reserve

ADBE

AMTM

NVDA

US Stocks Likely To Open Higher, Investors Eye Fed Policy Meet Next Week: Broadcom, RH, Costco In Focus

Shares of RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) rose sharply in the pre-market trading after the company <a href="https://www.benzinga.com/quote/RH/earnings">released quarterly results</a>.
RH posted downbeat earnings and sales results for its third quarter. However, the company raised revenue guidance across the board based on current trends. The company expects fourth-quarter demand growth of 20% to 22%, and fourth-quarter revenue growth of 18% to 20%, according to data from Benzinga Pro.
RH shares jumped 17.1% to $446.44 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Pearl Holdings Acquisition Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLH#NASDAQ">PRLH</a>) gained 44.1% to $17.50 in pre-market trading after adding 4% on Thursday.</li>
<li>Loop Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOOP#NASDAQ">LOOP</a>) gained 41.3% to $1.74 in pre-market trading. Loop Industries completed convertible preferred financing with Reed Societe Generale Group.</li>
<li>SPI Energy Co., Ltd.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPI#NASDAQ">SPI</a>) gained 39.5% to $0.4884 in pre-market trading after climbing around 14% on Thursday.</li>
<li>TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) gained 30.5% to $0.6785 in pre-market trading after jumping around 18% on Thursday.</li>
<li>Gaxos.ai Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GXAI#NASDAQ">GXAI</a>) rose 18.6% to $4.39 in pre-market trading after falling 27% on Thursday.</li>
<li>Lichen China Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) gained 16% to $0.2272 in pre-market trading after dipping more than 25% on Thursday. Lichen China announced a $2.70 million registered direct offering.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) gained 14.8% to $207.50 in pre-market trading as the company posted better-than-expected earnings for its fourth quarter. The company said it sees first-quarter revenue of approximately $14.6 billion, versus the $14.612 billion estimate. The company also issued adjusted EBITDA guidance of approximately 66 percent of projected revenue for the first quarter.</li>
<li>EVgo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) climbed 13.2% to $7.04 in pre-market trading. EVgo closed its $1.25 billion guaranteed loan facility from U.S. Department of Energy.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>) gained 12.4% to $1.27 in pre-market trading after falling around 10% on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) shares tumbled 35.8% to $2.55 in pre-market trading after the company reported results of Lunresertib and Camonsertib combination from MYTHIC Phase 1 gynecologic expansion clinical trial.</li>
<li>Nuburu, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>) declined 32.1% to $0.34 in pre-market trading after jumping 102% on Thursday.</li>
<li>Candel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares fell 30.9% to $6.77 in pre-market trading after the company announced the pricing of public offering.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) fell 22.8% to $2.90 in pre-market trading after the company announced a proposed public offering.</li>
<li>Comstock Holding Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHCI#NASDAQ">CHCI</a>) dipped 17.8% to $7.00 in pre-market trading after declining 4% on Thursday.</li>
<li>Actuate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) shares fell 15.5% to $7.00 in pre-market trading.</li>
<li>Northfield Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFBK#NASDAQ">NFBK</a>) fell 14.8% to $11.00 in pre-market trading.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) shares dipped 13% to $1.61 in pre-market trading. SEALSQ announced the pricing of $10 million registered direct offering.</li>
<li>Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) fell 9.8% to $12.50 in today's pre-market trading.</li>
<li>Kimball Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KE#NASDAQ">KE</a>) fell 4.5% to $18.32 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a></li>
</ul>

ACTU

BURU

CHCI

EVGO

GXAI

LAES

LICN

NFBK

PLRX

PRLH

Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) posted downbeat earnings and sales results for its third quarter. However, the company raised revenue guidance across the board based on current trends. The company expects fourth-quarter demand growth of 20% to 22%, and fourth-quarter revenue growth of 18% to 20%, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. RH shares jumped 17.7% to $448.70 in the after-hours trading session.</li>
<li>Wall Street expects 51Talk Online Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COE#NYSE">COE</a>) to report its unaudited financial results for the third quarter ended Sept. 30, before the opening bell. 51Talk Online Education shares fell 2.9% to $17.00 in after-hours trading.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) posted better-than-expected earnings for its fourth quarter. The company said it sees first-quarter revenue of approximately $14.6 billion, versus the $14.612 billion estimate. The company also issued adjusted EBITDA guidance of approximately 66 percent of projected revenue for the first quarter. Broadcom shares jumped 14.1% to $206.10 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) announced a proposed public offering. Inovio Pharmaceuticals shares dipped 21% to $2.9696 in the after-hours trading session.</li>
<li>Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) reported upbeat results for its first quarter on Thursday. The company reported first-quarter revenue of $62.15 billion, beating the consensus estimate of $62.08 billion. Costco shares fell 0.6% to close at $988.39 on Thursday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a></li>
</ul>
Photo courtesy: Shutterstock

RH, Broadcom And 3 Stocks To Watch Heading Into Friday

Inovio Pharmaceuticals shares are trading lower after the company announced a proposed public offering with terms or size not yet disclosed.

INOVIO Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the securities in the proposed offering will be sold by INOVIO. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Oppenheimer &amp; Co. Inc. and Citizens JMP are acting as joint book-running managers for the offering. Stephens Inc. is acting as lead manager for the offering.

INOVIO Announces Proposed Public Offering; No Size Or Amount Disclosed

INOVIO Announces Data From Retrospective Trial Showing The Number Of RRP Patients Meeting The Criteria For A Complete Response Increased To 50% By The End Of The Second Year Following Initial Treatment With INO-3107 In A Previously Reported Phase 1/2 52-week Trial

<a href="https://worldhealthorg.shinyapps.io/mpx_global/" title="https://worldhealthorg.shinyapps.io/mpx_global/">https://worldhealthorg.shinyapps.io/mpx_global/</a>

AEMD

APDN

CMRX

GOVX

TNXP

VRAX

World Health Organization Says Mpox Continues To Constitute A Public Health Emergency Of International Concern

Analysts' ratings for Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $8.25, a high estimate of $15.00, and a low estimate of $5.00. A decline of 45.0% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1731960078_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Inovio Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Inovio Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Inovio Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Inovio Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Inovio Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Inovio Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Inovio Pharmaceuticals</h2>
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
<h3>Inovio Pharmaceuticals: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Inovio Pharmaceuticals faced challenges, resulting in a decline of approximately -55.41% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -31993.31%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -33.72%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Inovio Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -24.52%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Inovio Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.13, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Analyst Landscape: 4 Takes On Inovio Pharmaceuticals

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Neutral and lowers the price target from $12 to $5.

Price Target

HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $5

Oppenheimer analyst Jay Olson maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Outperform and lowers the price target from $33 to $15.

Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Lowers Price Target to $15

RBC Capital analyst Gregory Renza maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Sector Perform and lowers the price target from $7 to $6.

RBC Capital Maintains Sector Perform on Inovio Pharmaceuticals, Lowers Price Target to $6

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.&#8217;s nomination to lead the&nbsp;Department of <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">Health and Human Services</a>.
Kennedy has been known to be against vaccines and has a track record of making false claims about vaccines, including the debunked idea that they cause autism. Scientific studies have <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">debunked this theory</a>.
Also, given his critical stance on mainstream medical practices and vaccines, U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH) employees are worried about Kennedy <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42009107/robert-kennedy-poised-to-lead-health-and-human-services-why-fda-nih-officials-are-nervous" rel="noreferrer noopener">being in charge</a>.
Kennedy, who received Trump&#8217;s blessing to &#8220;<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/11/41828359/could-trumps-go-wild-on-health-invite-to-rfk-jr-drive-changes-for-cannabis-and-psychedelics" rel="noreferrer noopener">go wild on health</a>,&#8221; has stated intentions to overhaul various aspects of the federal health agencies.
In a post on social media, Kennedy <a target="_blank" href="https://x.com/RobertKennedyJr/status/1857198805919138235" rel="noreferrer noopener">said</a>, &#8220;Together we will clean up corruption, stop the revolving door between industry and government, and return our health agencies to their rich tradition of gold-standard, evidence-based science. I will provide Americans with transparency and access to all the data so they can make informed choices for themselves and their families.&#8221;
On Friday, the World Health Organization also defended vaccines describing them as &#8220;absolutely critical&#8221; to global health, adding that many people alive today would not have survived <a href="https://www.benzinga.com/general/biotech/24/11/42006119/who-calls-vaccines-absolutely-critical-as-trumps-appointment-of-rfk-jr-pulls-pzifer-moderna-stocks-downhill" target="_blank" rel="noreferrer noopener">childhood without them</a>.
European vaccine player stocks declined, including&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Valneva SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41715307/biontech-variant-adapted-covid-19-vaccines-do-well-in-q3" rel="noreferrer noopener">BioNTech SE</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
GSK stock fell after the company reported lower third-quarter sales, which was impacted by an 18% decline <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41624198/gsks-q3-earnings-hit-by-lower-than-expected-vaccine-sales-cautions-lower-revenue-for-2024" rel="noreferrer noopener">in vaccine sales</a>.
COVID-19 vaccine players <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener">Moderna Inc</a><a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener"> </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" rel="noreferrer noopener">Pfizer Inc</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and BioNTech stock gained when the third quarter earnings surpassed estimates on increased vaccine demand.
Other vaccine players&#8217; stocks that are down include Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Inovio Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>).
Price Action: GSK stock is down 3.88% at $33.06, BNTX stock is down 5.18%, VALN stock is down 4.24%, AZN stock is down 2.08%, MRK stock is down 3.28%, INO stock is down 9.85% at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants" target="_blank" rel="noreferrer noopener">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></li>
</ul>
Photo by Vladimka production via Shutterstock

Large Cap

BNTX

MRNA

VALN

European And US Vaccine Stocks Are Under Pressure - Here's WHy

Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate of $(1.15) by 22.61 percent.

Earnings Beats

Inovio Pharmaceuticals Q3 2024 GAAP EPS $(0.89) Beats $(1.15) Estimate

In a report released on December 3, Roy Buchanan from JMP Securities reiterated a Buy rating on Inovio Pharmaceuticals (INO – Research Report), wit...

Inovio Pharmaceuticals' INO-3107 Shows Promising Clinical Trial Results, Earns 'Buy' Rating from Analyst

INOVIO Pharmaceuticals announces proposed public offering

Inovio (INO) Pharmaceuticals announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of...

Inovio announces common stock and warrants offering, no amount given

INOVIO stock slides after pricing $30M equity offering

The deal priced below last closing price of $3.76. Oppenheimer and JMP Securities are acting as joint book running managers for the offering. Publi...

Inovio 10M share Spot Secondary priced at $3.00

Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER – Penn Entertainment&nbsp;(PENN) up 5% after JPMorgan upgr...

Morning Movers: Penn Entertainment rises following upgrade

Inovio Pharmaceuticals: The Dangerous Allure Of A Falling Knife

Catalyst Watch: Labor pains for Amazon & Starbucks, Nasdaq call-up for MicroStrategy and Pony AI ratings

Investors Looking To Durable Goods, New-Home Sales Data As Earnings Season Winds Down

Catalyst Watch: Eyes on electric vehicle deliveries, retail data and housing reads

ABAT

ALMS

AMZN

ATRA

AXON

BYND

CRVL

CRVO

CVLG

DXST

ELVA

GALT

GLATF

GOEV

HOUR

IIPR

ILMN

KELYA

KULR

LCID

LMNR

LPTH

LPTX

MESO

MSTR

NDSN

NMRA

NUKK

PENN

PLTR

PONY

PSNY

QMCO

QRVO

QUBT

RIVN

RYTM

SAVA

SBUX

SLNO

SMCI

SWTX

TSLA

WBTN

WDAY

XPEV

Press Releases

INOVIO Reports Inducement Grants Under Inducement Plan

INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP

INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024

INOVIO to Present at Upcoming Scientific Conferences

Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

INOVIO Reports Inducement Grant Under Inducement Plan

New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

INOVIO Announces Proposed Public Offering

INOVIO Announces Pricing of $30 Million Public Offering

Agenus

Annovis Bio

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

BeyondSpring

Cue Biopharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

FibroBiologics

Gain Therapeutics

Generation Bio

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

Comments

Inovio Pharmaceuticals

뉴스

에 대한 최신 뉴스 Inovio Pharmaceuticals (NASDAQ:INO) 주식

금요일, 12월 13, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌